Jena, Germany
InflaRx, founded in 2007, is a Germany-based biopharmaceutical company recognized for pioneering anti-inflammatory therapeutics. The company's slogan, "Controlling Inflammation - developing drugs to treat life threatening and chronic inflammatory diseases," clearly reflects its mission.
At the core of InflaRx's innovation are its proprietary anti-C5a and anti-C5aR technologies, which target the complement activation factor C5a, a significant player in inflammatory diseases. Their flagship product candidate, vilobelimab, is a first-in-class monoclonal antibody that has shown promising results in clinical trials. The development of INF904, an oral small molecule inhibitor, further diversifies their portfolio.
With headquarters and key offices in Germany and the USA, InflaRx continues to expand its global footprint. The recent post-IPO equity investment of $40.00M on April 11, 2023, underscores confidence in its growth trajectory and innovation pipeline, making it a notable contender in the pharmaceutical sector.
